Alvotech (NasdaqGM:ALVO) is back in focus after the U.S. Food and Drug Administration closed its May 2026 inspection of the Reykjavik manufacturing facility with a Voluntary Action Indicated classification.

The FDA update and fresh BLA activity have arrived during a sharp swing in sentiment toward Alvotech, with a 7 day share price return of 23.87% contrasting with a year to date share price decline of 23.20% and a 1 year total shareholder return that is down 55.45%. Together, these figures indicate that short term momentum is improving after a tougher longer term experience for holders.

If you are looking beyond Alvotech and want to see where similar regulatory and product catalysts might emerge next, this is a good moment to scan 41 healthcare AI stocks

Bulls argue Alvotech’s recent FDA progress and biosimilar breadth are not reflected in the share price. Bears point to ongoing losses and a weak multi year return. Which story do the current valuation markers back up?

Most Popular Narrative: 72.2% Undervalued

Alvotech’s most followed narrative points to a fair value of $13.83 per share versus the last close at $3.84. This highlights a large gap between the model outputs and where the market is pricing the stock today.

Ongoing launch and approval pipeline activity, including upcoming regulatory decisions in major global markets (for AVT03, AVT05, AVT23, and others), positions the company to tap into blockbuster biologic markets coming off-patent, potentially driving a step-change in topline revenue once approvals are secured.

Curious what has to happen for that valuation to make sense. The narrative leans on faster revenue expansion, rising margins and a richer future earnings multiple. The full story shows how those moving parts fit together to reach $13.83.

Result: Fair Value of $13.83 (UNDERVALUED)

However, Alvotech's reliance on unpredictable milestone payments and its high debt load above US$1.1b mean that delays or weaker launches could quickly strain the current upside case.

Next Steps

The mix of optimism and concern around Alvotech is clear, so this is a good time to move quickly, review the underlying data, and weigh both sides through the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Alvotech?

Do not stop with a single stock story. Use the Simply Wall St Screener to quickly surface fresh ideas and pressure test your thinking before the next move.

• Spot potential mispricings fast by running through 52 high quality undervalued stocks that combine quality fundamentals with more modest market expectations.
• Strengthen your downside protection by checking 82 resilient stocks with low risk scores built around companies with more resilient risk profiles.
• Get ahead of the crowd by scanning a screener containing 18 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.